y Advisor (2007-2010) for the U.S. Department of Health and Human Services (HHS). In these positions, Dr. Fuerst led the development and acquisition of vaccines and biotherapeutic products for biodefense and other emerging public health threats, including anthrax, smallpox, botulism, and pandemic flu. During his tenure at HHS, he helped establish the Biomedical Advanced Research and Development Authority (BARDA) and oversaw the planning, implementation, and monitoring of medical countermeasure development and acquisition, while managing a budget of approximately $3.0 billion.
Previously, Dr. Fuerst served as Executive Director of Corporate Development at Sanofi Pasteur, Inc., where he oversaw the scientific and business transactions for vaccines and immunotherapeutic products for infectious diseases and cancer, and played a key role in establishing the company's biodefense initiative post 9/11. He also led a collaborative R&D group to develop a next generation anthrax vaccine in response to the National Institute of Health's Request for Proposal. Prior thereto, he was Vice President, Research and Development, at Genelabs Technologies, and a scientific founder and Director of Molecular Genetics, at MedImmune. He also served as a senior fellow at the National Institutes of Health, NIAID, in Bethesda, MD. Dr. Fuerst holds a B.A. in Biochemistry from the University of California at Berkeley, a Ph.D. in Molecular Genetics from Cornell University, and a MBA in Science, Technology, and Innovation from the George Washington University.
Ms. Linna, who was recently appointed to the position of Vice President of Program Management, brings more than 23 years of experience in drug development, with extensive experience building global project management offices in the biotechnology and pharmaceutical industries. Most recently, she served as the Executive Director of Project Management at Novavax Inc., with global project manaPage: 1 2 3 4 5 6 Related biology technology :1
. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®2
. PharmAthene Reports Third Quarter 2010 Financial and Operational Results3
. PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,0004
. PharmAthene Announces Pricing of $15 Million Public Offering5
. PharmAthene Announces Proposed Common Stock Offering6
. PharmAthene Announces $3.9 Million Registered Direct Offering7
. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference8
. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors9
. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies10
. PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 201011
. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010